Stockscreener 앱 받기
0.7951
0.35%
-0.0072
전일 마감가:
$0.8023
열려 있는:
$0.79
하루 거래량:
28,716
Relative Volume:
0.04
시가총액:
$22.26M
수익:
-
순이익/손실:
$-75.80M
주가수익비율:
-0.1728
EPS:
-4.6004
순현금흐름:
$-77.17M
1주 성능:
+16.83%
1개월 성능:
-34.47%
6개월 성능:
-66.69%
1년 성능:
-80.78%
1일 변동 폭
$0.79
$0.8099
1주일 범위
$0.623
$0.868
52주 변동 폭
$0.623
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.7951 | 22.46M | 0 | -75.80M | -77.17M | -4.6004 |
VRTX
Vertex Pharmaceuticals Inc
|
435.47 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.97 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
801.67 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.76 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 재개 | UBS | Neutral |
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Insider Monkey
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga
Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks
Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Australia
Citizens reiterates Jasper Therapeutics stock rating on CEO change - Investing.com
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - TipRanks
Jasper Therapeutics stock gains 5% on clinical progress despite Q4 loss - Investing.com India
MINISO Group Holding Limited (MNSO) Reports Q4 Earnings - news.alphastreet.com
Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings - AlphaStreet
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - Bitget
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c) - TipRanks
Jasper Therapeutics (JSPR) 10-K focuses on briquilimab mast cell programs and funding needs - Stock Titan
JSPR: Strong clinical progress but increased net loss and lower cash reserves highlight funding needs - TradingView — Track All Markets
Jasper Therapeutics (NASDAQ: JSPR) posts $75.8M 2025 loss, cash at $28.7M - Stock Titan
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Jasper Therapeutics 4Q Loss $9.1M >JSPR - moomoo.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Jasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92 - MSN
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88 - Defense World
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab - Yahoo Finance
Jasper Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
JSPR Stock Price, Quote & Chart | JASPER THERAPEUTICS INC (NASDAQ:JSPR) - ChartMill
Jasper Therapeutics Inc (JSPR) Stock News & Articles - 24/7 Wall St.
Jasper Therapeutics stock surges on positive briquilimab trial data amid mast cell therapy race - AD HOC NEWS
UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25 - marketscreener.com
UBS initiates Jasper Therapeutics stock rating at Neutral on competition By Investing.com - Investing.com Canada
UBS initiates Jasper Therapeutics stock rating at Neutral on competition - Investing.com
If You Invested $1,000 in Jasper Therapeutics Inc (JSPR) - Stock Titan
Jasper Therapeutics stock surges on positive briquilimab trial data for mast cell diseases - AD HOC NEWS
JSPR Should I Buy - Intellectia AI
Jasper Therapeutics, Inc. (JSPRW) Competitors - Meyka
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
How Jasper Therapeutics Inc. stock compares to industry benchmarksQuarterly Portfolio Review & Weekly High Return Forecasts - Naître et grandir
Aug Opening: How Jasper Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Snapshot & Pattern Based Trade Signal System - Naître et grandir
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
JSPR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
JSPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Millennium-linked firms report ~5.8% holdings in Jasper Therapeutics (JSPR) - Stock Titan
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.62%
자본화:
|
볼륨(24시간):